Drug
Lou064
Lou064: highest development phase Phase 2, developed by Novartis. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| LOU064 NCT07681271 | Phase 2 | Papulopustular Rosacea |
| LOU064 NCT07855276 | Phase 1 | Hidradenitis Suppurativa |
Latest
No recent events.
Follow Lou064 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.